Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Lundbeck Canada Inc. v. Cobalt Pharmaceuticals Inc. (now Actavis)

Fasken
Reading Time 1 minute read Subscribe

Overview

Proceedings to prohibit the Minister of Health from issuing a notice of compliance which would allow the sale, by Cobalt, of a generic version of escitalopram, a drug used in the treatment of depression, until the expiry of Canadian patent no 1,339,452. The patent at issue covers escitalopram itself, an enantiomer of citalopram. The application of Lundbeck was granted on February 12, 2009. The appeal of Genpharm was dismissed on November 25, 2010. The motion of Cobalt for leave to appeal to the Supreme Court of Canada was dismissed on August 25, 2011. Lundbeck was advised in these proceedings by a team from Fasken Martineau that included Marie Lafleur, Julie Desrosiers and Christian Leblanc. For more information, see (2009) FC 146, (2010) FCA 320 and (2011) SCCA No 32.

Team

    Subscribe

    Receive email updates from our team

    Subscribe